Carbogen Amcis, a Swiss firm specializing in active pharmaceutical ingredients (APIs) and pharmaceutical process development, has announced that its Shanghai facility has successfully passed its inaugural routine inspection by Brazil’s National Health Surveillance Agency (ANVISA). The five-day inspection in November 2023 has resulted in the site being awarded Good Manufacturing Practice (GMP) status by ANVISA, a significant accreditation in the pharmaceutical industry.
The Shanghai site, which is a crucial part of Carbogen Amcis’ global operations, employs 140 people and is specialized in the large-scale manufacturing of raw materials, intermediates, and APIs. It also manufactures highly potent chemicals up to category III and provides GMP product release along with analytical support for development activities. This GMP status not only underscores the site’s commitment to quality and safety but also enhances its position as a reliable partner for pharmaceutical companies seeking high-quality manufacturing services.
The achievement of GMP status by ANVISA is a testament to Carbogen Amcis’ continuous efforts in maintaining the highest standards in manufacturing practices and is expected to open new avenues for the company in the Brazilian market and beyond.- Flcube.com
